What it's for (Indications)
- This fixed-dose combination medication, containing amlodipine and atorvastatin, is indicated for patients for whom treatment with both amlodipine and atorvastatin is appropriate.
- Amlodipine, a dihydropyridine calcium channel blocker, is primarily used for the treatment of hypertension and for the management of chronic stable angina and vasospastic angina (Prinzmetal's angina).
- Atorvastatin, an HMG-CoA reductase inhibitor, is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adult patients with primary hypercholesterolemia or mixed dyslipidemia, and to increase HDL-cholesterol.
- It is also used to reduce the risk of cardiovascular events in patients with multiple risk factors.
- The combination is particularly beneficial for patients with co-existing hypertension and dyslipidemia, or those at high risk for cardiovascular events requiring comprehensive management of both conditions simultaneously.
- This approach simplifies medication regimens and can improve patient adherence to therapy, thereby enhancing overall cardiovascular risk reduction strategies.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended initial and maintenance dosage of amlodipine and atorvastatin combination therapy should be individualized based on the efficacy and tolerability of each component in the patient. The typical starting dose often aligns with the previously tolerated dosages of individual components. For example, a 10mg/10mg formulation contains 10 mg of amlodipine and 10 mg of atorvastatin calcium. This medication is usually administered orally, once daily, at any time of the day, with or without food. Dosage adjustments should be made cautiously, typically after 2 to 4 weeks, considering lipid levels, blood pressure response, and adverse reactions. Dose modification is crucial in patients with severe renal impairment or hepatic impairment, and concurrent use with strong CYP3A4 inhibitors requires careful consideration and potential dose reduction of atorvastatin to mitigate risks. Maximum recommended doses for each component should not be exceeded and are guided by individual component prescribing information. Adherence to a consistent daily dosing schedule is recommended to maintain optimal therapeutic levels. |
Safety & Warnings
Common Side Effects
- Patients taking amlodipine and atorvastatin may experience a range of side effects.
- Common adverse reactions attributed to amlodipine include peripheral edema (swelling of the ankles/feet), headache, flushing, fatigue, dizziness, nausea, and palpitations.
- These are generally mild to moderate and often dose-related.
- For atorvastatin, common side effects include myalgia (muscle pain), arthralgia (joint pain), nasopharyngitis, diarrhea, dyspepsia, and nausea.
- Less common but serious side effects associated with atorvastatin include myopathy and rhabdomyolysis, characterized by muscle pain, tenderness, or weakness accompanied by elevated creatine kinase levels; this can lead to acute renal failure.
- Liver enzyme elevations (transaminitis) have also been reported and require monitoring.
- Rare but serious effects from amlodipine can include marked hypotension or exacerbation of angina, particularly upon initiation or dose escalation.
- New-onset diabetes mellitus has also been observed with statin therapy.
- Patients should be advised to report any persistent or severe adverse reactions, especially unexplained muscle pain, dark urine, or yellowing of the skin or eyes, to their healthcare provider promptly for evaluation and management.
Serious Warnings
- Black Box Warning: This fixed-dose combination product of amlodipine and atorvastatin does not carry a formal FDA-mandated Black Box Warning. However, healthcare professionals and patients must be acutely aware of several serious safety concerns associated with its components. For the atorvastatin component, there is a significant risk of myopathy, including rhabdomyolysis, which can lead to acute renal failure secondary to myoglobinuria. This risk is dose-related and increased with co-administration of strong CYP3A4 inhibitors, fibrates, or niacin. Furthermore, statin therapy can cause liver dysfunction, necessitating liver function tests before and during treatment. Atorvastatin is also contraindicated in pregnancy and lactation due to potential fetal harm and infant toxicity, respectively. For the amlodipine component, serious warnings include the potential for symptomatic hypotension, especially with initial dosing or titration, and the rare possibility of worsening angina or acute myocardial infarction, particularly in patients with severe obstructive coronary artery disease upon initiation of calcium channel blocker therapy. Close monitoring for these serious adverse events is paramount throughout the treatment course.
- Several critical warnings are associated with amlodipine and atorvastatin therapy.
- Amlodipine should be used with caution in patients with severe aortic stenosis, severe obstructive coronary artery disease, or heart failure, as its vasodilatory effects can potentially exacerbate these conditions or lead to symptomatic hypotension, especially at initiation or dose increase.
- Atorvastatin therapy requires careful monitoring for potential hepatotoxicity; liver function tests should be performed before initiation and periodically thereafter.
- The risk of myopathy and rhabdomyolysis is a significant concern with statins, increasing with higher doses, advanced age, renal impairment, and concomitant use of certain drugs, particularly strong CYP3A4 inhibitors (e.
- g.
- , clarithromycin, itraconazole), fibrates, and niacin.
- Patients should be advised to report unexplained muscle pain, tenderness, or weakness immediately.
- New-onset diabetes mellitus has been reported with statin use.
- Furthermore, there is a small risk of reversible cognitive impairment, such as memory loss or confusion.
- Both components can have additive effects on blood pressure and lipid lowering, necessitating careful titration and patient monitoring to avoid excessive effects or adverse reactions.
- Discontinuation may be necessary if severe adverse reactions occur.
How it Works (Mechanism of Action)
This combination medication exerts its therapeutic effects through two distinct, yet complementary, pharmacological mechanisms addressing both hypertension and dyslipidemia. Amlodipine, a dihydropyridine calcium channel blocker, selectively inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle cells. This inhibition leads to relaxation of peripheral arterial smooth muscle, resulting in a reduction in peripheral vascular resistance (afterload) and a subsequent decrease in systemic blood pressure. It also dilates coronary arteries and arterioles, increasing myocardial oxygen delivery in patients with angina. Atorvastatin operates by selectively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. By blocking this enzyme, atorvastatin reduces the production of mevalonate, a precursor to cholesterol, primarily in the liver. This reduction in hepatic cholesterol synthesis stimulates an increase in the number of LDL receptors on hepatocyte surfaces, enhancing the uptake and catabolism of circulating LDL cholesterol. It also reduces very-low-density lipoprotein (VLDL) and triglyceride levels and can mildly increase high-density lipoprotein (HDL) levels.